Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
-
If you are wondering whether ABIVAX Société Anonyme is attractively priced at its current level, the key question is how that share price lines up against its underlying fundamentals.
-
The stock last closed at €101.40, with returns of 13.7% over 7 days, 7.9% over 30 days, an 11.8% decline year to date, and a very large gain over 1 year and 3 years. This suggests a meaningful shift in how the market is viewing the company.
-
Recent attention on ABIVAX Société Anonyme has focused on its moves within the pharmaceuticals and biotech space and how investors are reacting to its progress on key assets and funding. This context helps explain why the share price has moved so sharply over different time frames and why many investors are reassessing what they are willing to pay for the stock today.
-
The company currently has a valuation score of 2 out of 6, which reflects how often it screens as undervalued across several checks. The sections that follow will compare different valuation approaches before finishing with a broader framework that can help you judge whether that score fits your view of the stock.
ABIVAX Société Anonyme scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown .
Approach 1: ABIVAX Société Anonyme Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a present value. For ABIVAX Société Anonyme, this is done using a 2 Stage Free Cash Flow to Equity model that starts from current free cash flow and then moves into longer term projections.
The latest twelve month free cash flow stands at a loss of €161.36 million. Analysts provide explicit free cash flow estimates up to 2030, with a projected free cash flow of €692 million in that year. Beyond this point, Simply Wall St extrapolates additional free cash flow projections out to 2035 using the earlier data as a base.
When all these projected cash flows in € are discounted back to today, the model arrives at an estimated intrinsic value of about €677.88 per share. Compared with a recent share price of €101.40, the DCF suggests the stock trades at an implied discount of around 85.0%, which indicates it screens as significantly undervalued on this model.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests ABIVAX Société Anonyme is undervalued by 85.0%. Track this in your watchlist or portfolio , or discover 245 more high quality undervalued stocks .
Approach 2: ABIVAX Société Anonyme Price vs Book
For companies where book value is a meaningful anchor, the P/B ratio is a common way to think about what you are paying for the net assets on the balance sheet. Investors usually look for a P/B that lines up with their expectations for future growth and the level of risk they are taking on.
Higher growth potential and lower perceived risk can justify a higher P/B, while slower growth or higher risk usually call for a lower, more conservative multiple. That is why it helps to compare a stock’s P/B to a few reference points rather than in isolation.
ABIVAX Société Anonyme currently trades on a P/B of 17.64x. This is well above the Biotechs industry average P/B of 3.50x and also above the peer group average of 6.09x. On these simple comparisons, the shares look expensive relative to book value.
Simply Wall St’s Fair Ratio is designed to refine that view by estimating what P/B might be reasonable for ABIVAX Société Anonyme after considering factors such as earnings growth, profit margins, industry, market cap and key risks. Because it adjusts for these company specific drivers, the Fair Ratio can be more informative than headline peer or industry averages when judging whether the current 17.64x P/B looks stretched, conservative or somewhere in between.
Result: OVERVALUED
P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 96 top founder-led companies .
Upgrade Your Decision Making: Choose your ABIVAX Société Anonyme Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in, giving you a simple story that connects your view of ABIVAX Société Anonyme with the numbers behind it.
A Narrative is your explanation of what you think is happening at the company, tied directly to your own assumptions for future revenue, earnings and margins, which then flow through to a fair value estimate.
On Simply Wall St, Narratives sit on the Community page and are designed to be easy to use. They link a company’s story to a financial forecast and then to a fair value that you can compare with the current share price to help decide whether it might be a time to buy, hold or sell.
Narratives on the platform are refreshed when new information appears, such as company announcements, news or earnings updates. You can see, for example, one ABIVAX Société Anonyme Narrative that assumes a very conservative outlook and low fair value alongside another that reflects a more optimistic view and higher fair value, giving you a clear sense of the range of opinions in the market.
Do you think there's more to the story for ABIVAX Société Anonyme? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ABVX.PA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
